A Metabolic Vulnerability of Vision

New therapies targeting metabolic vulnerabilities of specific tumor types have created wide interest in recent years. Through research now reported in the Journal by Gantner et al.,1 metabolic precision therapy may become possible in patients with a rare eye disease, macular telangiectasia type 2, which leads to a progressive loss of central vision in both eyes in middle-aged or older persons.2 The macula is the small area in the back of the eye that is responsible for high-resolution (i.e., sharp) vision. In the center of the macula is the fovea, which has the highest density of cone photoreceptor cells and . . .